# Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor

> **NCT07660666** · NA · NOT_YET_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Electronic Health Record Review
- **OTHER:** Internet-Based Intervention
- **BEHAVIORAL:** Patient Navigation
- **OTHER:** Survey Administration
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT07660666
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2029-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660666, "Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07660666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*